Search
Gabexate
go.drugbank.com/drugs/DB12831InvestigationalGabexate is a synthetic serine protease inhibitor which has been used as an anticoagulant. It also known to decrease production of inflammatory cytokines.
Apramycin
go.drugbank.com/drugs/DB04626InvestigationalVet approvedApramycin is an aminoglycoside antibiotic and has a bactericidal action against many gram-negative bacteria.
NXN-188
go.drugbank.com/drugs/DB06096InvestigationalNXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.
Neovastat
go.drugbank.com/drugs/DB05387InvestigationalNeovastat is a naturally occurring anti-angiogenic compound, extracted from cartilage, with multiple anti-angiogenic mechanisms of action that provide broad therapeutic potential for a number of diseases. It is currently in international...
AME-527
go.drugbank.com/drugs/DB05879ExperimentalAME-527 is a humanized monoclonal antibody that recognizes human TNF-alpha (hTNF-alpha) with high affinity and specificity. AME-527 was generated by protein engineering and identified from a library of antibody variants based on its impr...
Relugolix
go.drugbank.com/drugs/DB11853ApprovedInvestigational[L27991,L27996] This branded product was later approved by the European Commission on April 29, 2022.[L42150] Relugolix has also been studied in the symptomatic treatment of endometriosis.
Categories: Sex Hormones and InsulinsRaseglurant
go.drugbank.com/drugs/DB05070InvestigationalADX10059 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM). The orally available small molecule drug candidate, which is highly specific for mGluR5, was discovered at Addex in 2003. It is developed for t...
Dirithromycin
go.drugbank.com/drugs/DB00954InvestigationalDirithromycin is a macrolide glycopeptide antibiotic used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections.
Albinterferon Alfa-2B
go.drugbank.com/drugs/DB05396InvestigationalThe drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C. … In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug.